The estimated Net Worth of Angelo Scopelianos is at least $1.34 Milion dollars as of 16 March 2024. Angelo Scopelianos owns over 27,906 units of Axogen stock worth over $778,261 and over the last 6 years he sold AXGN stock worth over $10,098. In addition, he makes $554,136 as Vice President - Research and Development at Axogen.
Sign up
Angelo Scopelianos AXGN stock SEC Form 4 insiders trading
Angelo has made over 6 trades of the Axogen stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 27,906 units of AXGN stock worth $370,592 on 16 March 2024.
The largest trade he's ever made was exercising 27,906 units of Axogen stock on 16 March 2024 worth over $370,592. On average, Angelo trades about 3,470 units every 73 days since 2018. As of 16 March 2024 he still owns at least 58,604 units of Axogen stock.
You can see the complete history of Angelo Scopelianos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Angelo Scopelianos biography
Dr. Angelo G. Scopelianos Ph.D. serves as Vice President - Research and Development of the Company. Dr. Scopelianos has served as Axogen’s Vice President of Research and Development since September 2018. From 2012 until joining Axogen, Dr. Scopelianos was an independent consultant specializing in medical devices. He began consulting after his retirement from a 24-year tenure at Johnson & Johnson (J&J). Angelo began at J&J in 1988 as section manager of R&D and held the escalating positions of manager of R&D, director of R&D, vice president of R&D and finally from October 2010 to September 2012 senior vice president of R&D. He joined J&J after research leadership positions at EI Dupont de Nemours in Wilmington, Delaware, and Pennwalt Corporation. Angelo received his doctorate degree in organic chemistry from Pennsylvania State University, following completion of a Bachelor of Science degree from the State University of New York—Oneonta. He holds over 35 U.S. patents and numerous international patents, and his awards include the Outstanding Science Alumni Award by Penn State University; the Scientific Leadership Award in Biomaterials Science awarded by a consortium of NJ research universities: Rutgers University, Princeton University and NJ Institute of Technology; the Johnson & Johnson Philip B. Hofmann Award for technical achievements in scientific research; and an Honorary Doctor of Science Degree bestowed by the State University of New York.
What is the salary of Angelo Scopelianos?
As the Vice President - Research and Development of Axogen, the total compensation of Angelo Scopelianos at Axogen is $554,136. There are 3 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.
How old is Angelo Scopelianos?
Angelo Scopelianos is 65, he's been the Vice President - Research and Development of Axogen since 2018. There are 2 older and 13 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
What's Angelo Scopelianos's mailing address?
Angelo's mailing address filed with the SEC is 13631 Progress Blvd #400, Alachua, FL 32615, USA.
Insiders trading at Axogen
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels a Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
What does Axogen do?
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
What does Axogen's logo look like?
Complete history of Angelo Scopelianos stock trades at Axogen
Axogen executives and stock owners
Axogen executives and other stock owners filed with the SEC include:
-
Eric Sandberg,
Chief Commercial Officer -
Karen Zaderej,
Chairman of the Board, President, Chief Executive Officer -
Gregory Freitag,
Director -
Angelo Scopelianos,
Vice President - Research and Development -
Peter Mariani,
Chief Financial Officer -
Maria Martinez,
Chief Human Resource Officer -
Quentin Blackford,
Independent Director -
Alan Levine,
Independent Director -
Amy Wendell,
Lead Independent Director -
Mark Gold,
Independent Director -
Guido Neels,
Independent Director -
Paul Thomas,
Director -
Brad Ottinger,
Chief Compliance Officer, General Counsel -
Isabelle Billet,
Chief Strategy and Business Development Officer -
Mark Friedman,
Vice President - Regulatory Affairs and Quality Assurance -
Erick DeVinney,
Vice President - Clinical and Translational Sciences -
Mike Donovan,
Vice President - Operations -
James E Deerfield Mgmt L.P....,
-
John P Engels,
Vice President -
Jamie Mark Grooms,
Director -
Robert James Rudelius,
Director -
Joseph M Mandato,
Director -
Shawn F Mccarrey,
SVP of Sales -
Lisa N Colleran,
Director -
Jon S. Gingrich,
Chief Commercial Officer -
Woodlands Fund Ix, L.P. Essex,
10% owner -
Kevin Leach,
Vice President Marketing -
Kathy Johnson Weiler,
Director -
William P. Mr. Burke,
Director -
Lee Robert Jr Johnston,
Chief Financial Officer -
Jill F Schiaparelli,
SVP, Bus. Strategy&Marketing -
John Frederick Harper,
Director -
Bradley Jay Hedger,
Vice President, Sales -
David K Hansen,
VP Finance & Treasurer -
Michael Patrick Donovan,
VP Operations -
Joseph A. Tyndall,
Director -
John Johnson,
Director -
Nir Naor,
CFO -
Marc A Began,
EVP and General Counsel -
Jens Kemp,
Chief Marketing Officer -
Michael D Dale,
CEO and President